Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2001 1
2002 1
2003 1
2004 1
2007 1
2013 1
2015 1
2016 1
2018 1
2019 1
2020 2
2021 1
2022 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
[Vesicovaginal fistula].
Cortesse A, Colau A. Cortesse A, et al. Among authors: colau a. Ann Urol (Paris). 2004 Apr;38(2):52-66. doi: 10.1016/j.anuro.2004.01.001. Ann Urol (Paris). 2004. PMID: 15195576 Review. French.
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; VESPER Trial Investigators. Pfister C, et al. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar. Contemp Clin Trials Commun. 2020. PMID: 32083220 Free PMC article.
Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
Arnaud Q, Sebe P, Colau A, Mouton M, Desgrandchamps F, Masson-Lecomte A, Bessede T, Irani J, Dominique I. Arnaud Q, et al. Among authors: colau a. Fr J Urol. 2024 Jan;34(1):102548. doi: 10.1016/j.purol.2023.10.002. Epub 2023 Nov 18. Fr J Urol. 2024. PMID: 37980231
The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival.
Nassif EF, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, Compérat E, Bindea G, Catteau A, Fugon A, Boquet I, Martel M, Camparo P, Colin P, Zakopoulou R, Bamias A, Bennamoun M, Barthere X, D'acremont B, Lefevre M, Audenet F, Mejean A, Verkarre V, Oudard S, Galon J. Nassif EF, et al. Among authors: colau a. Cancers (Basel). 2021 Jan 28;13(3):494. doi: 10.3390/cancers13030494. Cancers (Basel). 2021. PMID: 33525361 Free PMC article.
17 results